Filing of Form 10-Q

RNS Number : 9104K

MaxCyte, Inc.

10 May 2022

 

MaxCyte announces filing of Form 10-Q for the quarterly period ended March 31, 2022

GAITHERSBURG, MD, May 10, 2022 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization , today announced that it has filed a Form 10-Q with the SEC for the quarterly period ended March 31, 2022.

A copy of the Form 10-Q is available to view on the SEC's website at www.sec.gov and has also been posted to the "SEC filings" page of the Company's website, https://investors.maxcyte.com/ .

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser   Gilmartin Group   David Deuchler, CFA	[phone]   [e-mail]
Nominated Adviser and Joint Corporate Broker   Panmure Gordon   Emma Earl / Freddy Crossley   Corporate Broking   Rupert Dearden	[phone]
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh	[phone] [e-mail]

 

END

 

 

MSCBKKBPPBKKPPD